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Purpose: To investigate how arterial input functions (AIFs) vary with age in children and compare the use of individual
and population AIFs for calculating gray matter CBV values. Quantitative measures of cerebral blood volume (CBV)
using dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) require measurement of an AIF. AIFs are
affected by numerous factors including patient age. Few data presenting AIFs in the pediatric population exists.
Materials and Methods: Twenty-two previously treated pediatric brain tumor patients (mean age, 6.3 years; range, 2.0–
15.3 years) underwent DSC-MRI scans on a 3T MRI scanner over 36 visits. AIFs were measured in the middle cerebral
artery. A functional form of an adult population AIF was fitted to each AIF to obtain parameters reflecting AIF shape.
The relationship between parameters and age was assessed. Correlations between gray matter CBV values calculated
using the resulting population and individual patient AIFs were explored.
Results: There was a large variation in individual patient AIFs but correlations between AIF shape and age were
observed. The center (r5 0.596, P < 0.001) and width of the first-pass peak (r5 0.441, P5 0.007) were found to corre-
late significantly with age. Intrapatient coefficients of variation were significantly lower than interpatient values for all
parameters (P < 0.001). Differences in CBV values calculated with an overall population and age-specific population AIF
compared to those calculated with individual AIFs were 31.3% and 31.0%, respectively.
Conclusion: Parameters describing AIF shape correlate with patient age in line with expected changes in cardiac out-
put. In pediatric DSC-MRI studies individual patient AIFs are recommended.
J. MAGN. RESON. IMAGING 2016;43:981–989.
Dynamic susceptibility contrast (DSC) magnetic resonanceimaging (MRI) is a method used for measuring perfu-
sion in the brain and involves the injection of a paramagnetic
contrast agent.1,2 It provides estimates of parameters includ-
ing cerebral blood flow (CBF), cerebral blood volume
(CBV), and vascular mean transit time (MTT). It has been
widely used in the study of stroke3 and brain tumors.4–6 In
brain tumors it has been shown to be useful in tumor grad-
ing,4,7–9 differentiating between different types of brain
tumors,10 aiding treatment planning,11 assessing treatment
response,9 differentiating between treatment effects and recur-
rence,12–14 and predicting long-term patient outcome.15
The passage of injected contrast agent through the tis-
sue results in loss of MR signal intensity, which is related to
the concentration of contrast agent in the tissue. The concen-
tration of contrast agent in the tissue is expressed as the con-
volution of the arterial input function (AIF) and the tissue
residue function2—the fraction of contrast agent remaining
in the tissue at time, t—modulated by CBF. Absolute calcula-
tions of CBF can be obtained by performing deconvolution
of the tissue concentration–time curve and AIF and CBV can
be obtained by normalizing the area under the tissue concen-
tration–time curve by the area under the AIF.
The use of an AIF has some distinct advantages. While
relative estimates of CBF and CBV can be obtained from
the shape of the concentration–time curve alone, these will
vary due to the shape of the AIF and the MR protocol
employed. This makes comparisons between different
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scanners, sites, patients, and multiple visits by the same
patient difficult. Pediatric studies are often, by necessity,
multicenter due to small numbers of patients presenting at
each center and so methods of data acquisition and analysis,
including region of interest (ROI) definition, require stand-
ardization across centers. While many studies have presented
brain tumor CBV values normalized to either gray5,16 or
white matter,10,12,17 this does not take into account abnor-
malities that may occur due to treatment. Many pediatric
brain tumors occur in the mid-line, thereby excluding the
option of selecting contralateral normal brain. Normaliza-
tion to gray matter is usually inappropriate in these cases.
Gray matter CBVs may be of interest in their own right, for
example, when assessing treatment effects on neurocognitive
function. A recent study using simulated data showed that
DSC parameters were highly dependent on the patient AIF
and warned that parameters obtained from the shape of the
concentration–time curve should be treated with caution.18
Other studies19,20 have found good agreement between
DSC-MRI measures of CBF obtained using deconvolution
and CBF obtained using [15O]H2O positron emission
tomography (PET) and 133Xe SPECT, respectively, support-
ing the importance of using an AIF.
The AIF is a measure of the supply of contrast agent
to the tissue of interest.1,2,21 It is needed in order to remove
variations in the supply of contrast agent that arise due to
differences in patient physiology, including cardiac output
and vascular disease, as well as the injection dose and rate of
administration of contrast agent during the DSC examina-
tion.22 Ideally, an AIF is measured close to the tissue of
interest in order to minimize the effects of delay and disper-
sion of the contrast agent on the resulting signal–time
course. An AIF is usually obtained by direct measurement
of the change in contrast agent concentration during the
DSC examination and requires inclusion of a suitable vessel
within the MR field-of-view (FOV).
There are occasions when it may be difficult to measure
an AIF: for example, if there is no suitable artery within the
imaging FOV or where the accuracy of the AIF is in doubt.
This may occur if the temporal resolution of the DSC proto-
col is not sufficient to satisfactorily capture the first pass peak
of the AIF or if the suitable vessel within the FOV is small
in comparison to the spatial resolution of the DSC time
course, resulting in partial volume effects.21 In cases such as
these, an averaged AIF obtained from a similar patient popu-
lation has often been used.23–25 These are all based on studies
of AIFs in adults and show varying differences between AIFs
obtained in different patients. Due to the known variation of
cardiac output with age in children,26 it would be expected
that AIFs obtained from pediatric patients of different ages
would differ significantly from each other and from those
obtained in adults. Miyazaki et al27 presented an averaged
AIF obtained from six pediatric patients scanned using
dynamic contrast-enhanced (DCE) MRI and showed differ-
ences when compared to an adult population AIF.23
The aims of this work were therefore: 1) To investigate
the feasibility of measuring AIFs in a population of children
with brain tumors undergoing surveillance DSC-MRI scans
at our hospital, and 2) To investigate how the AIFs and
resulting CBV values vary with age.
Materials and Methods
MR scans were performed on a Philips Achieva 3T TX (Philips
Healthcare, Best, the Netherlands) using a 32-channel head coil.
The study was approved by the local research and ethics committee
and informed parental consent was obtained.
DSC-MRI was performed in addition to routine clinical
scans that included a high-resolution T2-weighted TSE scan with
the same coverage as the subsequent DSC scan for the purposes of
defining ROIs (relaxation time / echo time [TR/TE]5 4000/100
msec). The DSC-MRI scan was an axial FE-EPI scan28,29 (TR/
TE5 1865/40 msec, FOV5 240 3 240mm, matrix5 96 3 96)
with a low flip angle (208) to reduce the effect of T1 shortening in
the case of blood–brain barrier breakdown8 while still retaining
signal-to-noise. Thirty slices with a slice thickness of 3.5mm each
were acquired to cover the whole brain. The temporal resolution
of the DSC scan was 1.86 seconds, which was repeated 60 times.
Contrast agent (Dotarem, Guerbet, France) was administered via a
power injector through a cannula inserted in an antecubital vein.
The total dose of contrast agent given was 0.1 mmol/kg. This was
given in two stages: the first half-dose as a prebolus prior to the
DSC acquisition for minimization of T1 effects
8 and the second
half-dose at the start of timepoint 5 in the DSC data acquisition.
The injection rate used was 3mL/s, in line with recommendations
from the literature.30 Each half-dose of contrast was followed by a
volume of up to 10mL of saline injected at the same rate, with the
volume dependent on the patient’s weight.
Data were analyzed using software developed in-house using
the Python programming language (v. 2.7). The data were loaded
into viewing and a suitable slice depicting the middle cerebral artery
(MCA) was found. A 4 3 4 voxel square was placed on the left and
right MCAs, respectively, resulting in 16 AIFs—one from each voxel
in the square—for each side of the MCA. The 16 AIFs were
inspected visually for shape, height, depiction of first- and second-pass
peaks, and suitable AIFs from each side were averaged to produce an
AIF for the left and right MCAs, respectively. A gamma variate func-
tion31 was fit to the first pass of the left and right AIFs, respectively.
The AIF used for a patient was the “best” of the left and right AIFs
reflected by the lowest chi-squared value for the respective fits.
The number of AIFs averaged in each case was noted. All
AIF analyses were performed by the same researcher (S.W.). The
resulting signal–time curves were converted to contrast agent con-
centration using:
CðtÞ52 k
TE
ln
SðtÞ
Sð0Þ
 
(1)
where S(t) and S(0) are the signal intensities at time, t, and base-
line, respectively, TE is the time-to-echo of the DSC sequence,
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and k was assumed to be 1 for all patients. T1 effects were
assumed to be negligible in analysis and the baseline signal inten-
sity was calculated as the average signal intensity for the first six
timepoints.
AIFs were interpolated to 1-second temporal resolution and
manually time-shifted so that the last timepoint prior to the arrival
of contrast agent coincided with timepoint zero removing the vari-
ation in arrival of contrast due to the time of injection and differ-
ences in bolus arrival time between patients.
Patients were separated into populations by age (2–3 years,
3–5 years, 5–10 years, and >10 years) and a population AIF for
each age group was produced by averaging the AIFs of patients
within each group. Patient AIFs were fitted to the Parker popula-
tion AIF (Eq. (2)23 using software written in Python, to produce
estimates of parameters used to describe the shape of the AIF. The
starting estimates used were those presented previously.23 A nonlin-
ear least-squares minimization routine was performed.
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where: An5 scaling constant of nth Gaussian (mmol min);
Xn5 center of nth Gaussian (min); rn5width of nth Gaussian
(min); a5 amplitude of exponential (mmol); b5 decay constant
of exponential (min21); s5width of sigmoid (min21); and
s5 center of sigmoid (min).
Pixel-by-pixel CBV values were calculated using:
CBV5
Ð tmax
0 CtðtÞdtÐ tmax
0 CaðtÞdt
(3)
where Ct(t) is the contrast agent concentration for the pixel and
Ca(t) is the AIF. CBV maps were produced for each patient using:
1) the individual patient AIF, 2) the overall population AIF and, 3)
the age-specific population AIF for that patient. ROIs were then
defined in gray matter on high-resolution T2-weighted MR images.
The ROIs were transferred to the lower-resolution CBV maps and
an average CBV for the whole ROI was computed.
Statistical Analysis
Correlations between parameters and patient age were assessed.
Each of the fitted parameters was normalized for age and intra-
and interpatient coefficients of variability calculated using the root
mean square approach. A Kruskal–Wallis test was performed to
test whether the distributions of parameters were the same across
each of the age groups. Statistical analyses were carried out using
SPSS (Chicago, IL).
Results
Table 1 summarizes the details of the 22 patients who
underwent a total of 36 MRI scans. One patient underwent
DSC scans on five visits; two patients underwent DSC scans
on three visits; six patients underwent DSC scans on two
visits. The mean age of the patients was 6.3 (range 2.0–
15.3) years old. All except three examinations were per-
formed under general anesthetic. Seven of the patients had
undergone radiotherapy treatment prior to scanning. Four
of the patients had a diagnosis of neurofibromatosis type 1
(NF1). The average total dose of contrast agent given was
4.4 (range 2.0–16.0) mL with the bolus duration of the sec-
ond half-dose given during the DSC examination ranging
from 0.33–2.67 seconds. There was a significant correlation
between patient age and dose of contrast agent administered
(r5 0.803, P < 0.001). The average chi-squared values of
gamma variate fits to AIFs obtained from the left and right
branches of the MCA were 47.7 and 35.1, respectively.
The right AIF was the “better” AIF in 25 of the 36
examinations.
Figure 1a shows an example DSC image from a 6-
year-old boy along with the placement of the 4 3 4 voxel
box (Fig. 1a) from which AIFs from each of the 16 voxels
in the box were obtained (Fig. 1b). For this patient, five of
those AIFs were averaged to produce the patient AIF, which
was then converted from a signal intensity–time curve (Fig.
1c) to a concentration–time curve (Fig. 1d). The AIFs for
averaging were chosen manually based on shape of the sig-
nal–time curve and included only those voxels which were
fully located within the MCA.
TABLE 1. Details of Patients Included in the Study
Tumor type No. pts No. scans Mean age at date
of scan (yrs)
Mean age at date
of first scan (yrs)
OPG 2 3 4 4
OPG (NF1) 4 8 7 6
Pilocytic astrocytoma 3 8 8 10
Low grade glial neuronal tumors 3 4 6 7
Medulloblastoma 3 3 4 4
Other rare tumors 7 10 6 7
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Individual patient AIFs were averaged from a mean of 6
(range5 3–10) pixels. A large variation in the shape of AIFs
obtained from different patients was observed. Figure 2 shows
population AIFs for patients in the following age groups: 2–3
years old, 3–5 years old, 5–10 years old, and over 10 years
old. A difference in the population AIFs between age groups
can be observed—the population AIFs from younger patients
have sharper, more pronounced first- and second-pass peaks
than those from the older populations. A fit of the Parker
adult population AIF23 to a patient AIF is shown (Fig. 3).
Good fits of the Parker population AIF to all patient AIFs was
observed and are reflected in the chi-squared values obtained
(Table 2). The mean and standard deviation of parameters
obtained by averaging values obtained from fits to all patient
AIFs and over each age group are presented in Table 2. The
center of the first-pass peak was positively correlated with age
(Fig. 4a; X1: r5 0.596, P5<0.001). The width of the first-
pass peak was significantly correlated with age (Fig. 4c; r1:
r5 0.441, P5 0.007). The width and center of the second-
pass peak were not significantly correlated with age (Fig. 4b;
X2: r5 0.097, P5 0.572; Fig. 4d; r2: r5 0.172, P5 0.315).
The least-squares lines of best fit for parameters with age are
given in Fig. 4, allowing a population AIF to be determined
at any age using Equation (2) and additional information
from Table 2. A Kruskal–Wallis test showed that the distribu-
tions of the parameters X1 and r1 were not the same across
different age groups (P < 0.05 for both), while the distribu-
tions of other parameters with age group were not significantly
different at the 0.05 significance level.
AIFs obtained from the same patient scanned at five
different timepoints are shown in Fig. 5. Intrapatient coeffi-
cients of variation were significantly lower than interpatient
values for all AIF parameters (X1: 0.184 vs. 0.463, X2: 0.120
vs. 0.444, r1: 0.131 vs. 0.411, r2: 0.271 vs. 0.543, P <
0.001). AIFs obtained from the left and right MCAs showed
good agreement in all patients. A paired t-test performed on
the left and right shape parameters obtained showed that
there were no significant differences between the AIFs
obtained from each side; the P-values for all parameters were
greater than 0.05. An unpaired t-test showed no significant
differences between AIF parameters or any of the CBV values
measured in patients with NF1 and the rest of the population
and between parameters measured in patients previously
treated with radiotherapy and the rest of the population.
Example CBV maps obtained using each of the three
AIFs—patient AIF, age-specific AIF, and overall population
FIGURE 1: (a) Image from DSC-MRI scan showing slice and location from which AIFs were obtained; (b) AIFs from each of the 16
voxels in the 4 3 4 voxel square selected; (c) Signal–time curve of AIF obtained by averaging signal–time curves from 6 voxels in
the 4 3 4 voxel box. The error bars represent the standard error in the six individual pixel AIFs averaged to produce the final AIF
used for this patient; (d) Corresponding normalized concentration–time curve interpolated to have a temporal resolution of 1 sec-
ond. The patient was a 5-year-old girl with a pilocytic astrocytoma who received a contrast agent dose of 3mL.
Journal of Magnetic Resonance Imaging
984 Volume 43, No. 4
AIF—for a patient in the study where the individual patient
AIF was quite different from the population AIFs are shown in
Fig. 6. The range of gray matter CBVs observed over all patients
was lower in CBVs calculated using the individual patient AIFs
(mean6 SD5 5.176 1.83mL/100mL) than using the overall
population AIF (mean6 SD5 4.986 2.02mL/100mL) and
age-specific population AIF (mean6 SD5 4.986 2.01mL/
100mL).
The root mean square error in the CBV values calcu-
lated using a population and age-specific population AIF
compared to those calculated using individual patient AIFs
were 31.3% and 31.0%, respectively, with the individual
root mean square errors being significantly different from 0
for both the population and age-specific population AIFs
(paired t-test: P < 0.005 in both cases). Differences in the
values obtained when comparing the results obtained using
an individual patient AIF and each of the population AIFs
are shown in Bland-Altman plots (Fig. 7a,b).
Discussion
AIFs from 22 patients scanned over a total of 36 visits dem-
onstrated a large variation in their shape, which was reflected
in measures of the center and width of the first and second-
FIGURE 2: Graphs showing average normalized AIFs for: (a) all 22 patients scanned over 36 visits; (b) patients aged from 2–3
years old (n57); (c) patients aged from 3–5 years old (n510); (d) patients aged from 5–10 years old (n511); and (e) patients
aged over 10 years old (n58). Error bars show the standard error in average AIFs for each age group. Only the first 1.5 minutes
of the acquisition following the appearance of contrast in the MCA are shown to allow better visualization of the first- and
second-pass peaks.
FIGURE 3: Graph showing the AIF obtained from a 6-year-old
patient (circles) along with the fit of the Parker population AIF
to the data (dotted line).
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pass peaks. Fits of the AIFs to a functional form23 showed
that the central locations and width of the first peak were sig-
nificantly correlated with age. Use of these and other parame-
ters allows an age-specific population AIF to be determined.
Intrapatient variability in AIF parameters was significantly
less than interpatient variability, implying that patient charac-
teristics play a major role in determining AIF variability.
It is well known that cardiac output—the amount of
blood ejected from a ventricle in 1 minute—reduces with
age.26,32 As cardiac output lowers, less contrast will be
pumped from the ventricle in each heartbeat, with the result
that the contrast agent bolus becomes more spread out. As
the first-pass peak widens, the center of both peaks will shift
to longer times. In addition, older, larger patients will
FIGURE 4: Graphs showing relationship between age and (a) center of first-, X1; and (b) second-pass, X2, peaks; and (c) widths of
first-, r1; and (d) second-pass, r2, peaks.
TABLE 2. Mean and Standard Deviation (SD) of Fitted Parameters and Chi-Square Values Obtained Over All
Patient Visits (n5 36) and by Age Group
Mean6 SD of parameter
Parameter All (n5 36) 2–3 yrs (n5 7) 3–5 yrs (n5 10) 5–10 yrs (n5 11) > 10 yrs (n5 8)
A1 (mmol.min) 2.406 0.92 2.016 0.65 2.316 0.70 2.576 0.66 2.616 1.53
A2 (mmol.min) 1.626 0.62 1.556 0.78 1.266 0.54 1.786 0.46 1.916 0.62
X1 (min) 0.096 0.05 0.096 0.02 0.076 0.02 0.076 0.01 0.146 0.10
X2 (min) 0.246 0.05 0.236 0.04 0.256 0.04 0.256 0.03 0.246 0.08
r1 (min) 0.046 0.01 0.036 0.01 0.036 0.01 0.036 0.01 0.046 0.02
r2 (min) 0.076 0.03 0.076 0.03 0.066 0.02 0.096 0.03 0.076 0.03
a (mmol) 7.236 3.80 6.786 2.93 7.656 5.04 7.356 4.37 6.936 2.12
b (min21) 1.326 1.39 1.406 1.67 1.746 1.78 1.236 1.34 0.876 0.38
s (min21) 80.06 64.7 61.66 38.6 88.26 81.0 75.96 44.9 92.46 87.5
s (min) 0.346 0.11 0.326 0.11 0.316 0.08 0.416 0.07 0.296 0.014
Chi-sq 66.86 51.4 65.76 38.9 59.86 40.1 90.16 74.6 44.66 20.4
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receive higher doses of contrast agent, which along with the
increased length of the cardiac system will result in longer
contrast agent transit times and increased bolus delay and
dispersion.
The majority of DSC studies have sought to model
the first pass of contrast agent with a gamma variate func-
tion.2,18,31,33 Parameters obtained when applying a gamma
variate function to DSC-MRI data obtained in 36 children
aged 0.5 to 17.5 years old33 were shown to differ from
those obtained in six adults2 and show that the pediatric
first-pass peak occurs almost a second before that of the
adult AIF and has a width 4 seconds narrower than the
adult AIF. The functional form of the AIF used to model
the AIFs in our study was initially used for analysis of AIFs
obtained in DCE-MRI23 and comprises two Gaussians and
an exponential modulated with a sigmoid function. The
AIFs obtained in this study take the same form as those
measured using DCE-MRI; therefore, there is no reason to
suggest that the model is not valid in this dataset. X1 and
X2 in all age groups in our study were generally lower (X1:
range 0.035–0.373min; X2: range 0.105–0.369min) than
those presented by Parker et al in adults (X1: 0.17046min;
X2: 0.365min).
23 Similar patterns were observed for the
peak widths (r1 and r2), which were lower in our study
than in the adult study. A study presented by Miyazaki
et al27 compared a population AIF obtained using DCE-
MRI in six pediatric cancer patients with those presented in
the adult study.23 Their results agree well with ours: the
pediatric population AIF was found to have a more rapid,
narrower first-pass peak and more clearly defined recircula-
tion peak than the adult AIF.
Quantitative estimates of CBF, CBV, and MTT in
DSC-MRI require measurement of an AIF and have been
shown to be more accurate than the same parameters cal-
culated from the shape of the concentration–time curve
alone.18 While relative estimates of these parameters are of
use in brain tumor studies,5,10,12,16,17 quantitative esti-
mates allow comparison between patients in multicenter
studies, between scans obtained on different visits and
FIGURE 5: AIFs obtained from the left MCA of a patient
scanned at five different timepoints following treatment for a
pilocytic astrocytoma. The age of the patient at visit 1 was
5 years old. Subsequent visits were 4, 7, 14, and 16 months
following the first. The patient received doses of 1.5 mL,
1.4 mL, 1.5 mL, 1.6 mL, and 1.6mL at each subsequent visit
respectively.
FIGURE 6: AIFs and CBV maps for a 15-year-old male patient
with a subependymal giant cell astrocytoma. The individual
patient AIF for this patient differed from the age-specific (>10-
year group) AIF and the overall population AIF, so CBV values
were very different depending on the AIF used (3.97, 5.40,
5.86mL/100mL for mean gray matter CBV calculated using the
patient, age-specific, and population AIFs, respectively).
FIGURE 7: Bland–Altman plots showing the variation between
CBV values calculated using the two population AIFs: (a) age-
specific and, (b) overall population, and that calculated with
the individual patient AIF. 95% limits of agreement are shown.
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different scanners,18 and can be used in assessing gray mat-
ter CBV. The large variation in AIFs observed between
patients suggests that patient AIFs should be measured on
an individual basis wherever possible, in agreement with
other studies.22,25
Mean CBV values in adult gray matter have been
shown to range by between 3 and 7mL/100mL,34–37
although data analysis methods vary across these references.
No systematic errors in CBVs calculated with the respective
population AIFs were observed when compared to those cal-
culated with individual AIFs. Average differences of 30%
were observed, however, with the largest error reaching
70%. An error in CBV of this magnitude is unacceptable
when looking at changes in CBV values with treatment
which may be significantly smaller than the error due to the
AIF used. Gray matter CBVs in our study were also found
to have a smaller range when calculated using individual
AIFs. Taken together, these results suggest that variations in
patient AIF should be taken into account when calculating
CBV.
There are a number of potential limitations to this
study. The majority of our patients were scanned under gen-
eral anesthetic (GA). While studies suggest that the drugs
given may affect cardiac output,38 no significant difference
between AIF parameters in the GA and non-GA groups was
observed. The children included in the study have a variety
of brain tumors and have undergone various treatments for
their condition, both of which may affect the vasculature,
for example, radiotherapy and NF1.39 We observed no sig-
nificant differences between parameters in the small number
of patients with either NF1 or those treated with
radiotherapy.
Ideally, an AIF would be obtained from the artery
that directly supplies the tissue of interest, known as a
local AIF; however, supplying arteries tend to be small,
resulting in partial volume effects. In this study, a global
AIF was obtained from the left and right MCAs, and the
most appropriate AIF chosen. While the shape of the AIF
may be the closest to that expected, there is no guarantee
that this AIF is the most suitable AIF for subsequent analy-
sis of the DSC data, or that the AIF is not affected by the
abnormality in some way. The placing of the box over the
MCA and subsequent selection of suitable AIFs for averag-
ing were performed manually by the same user for consis-
tency. Studies have presented a variety of automated
methods40,41 for obtaining AIFs, which use software to
include or exclude voxels based on their shape. While these
remove the user-variability of the method, errors can still
arise if individual AIFs are not checked for shape and
location.
The number of patients included in the study was
small, resulting in large errors in the population AIFs and
resulting parameters. However, sufficient data exists to ascer-
tain significant differences in the parameters with age and
between some of the parameters across the different age
groups, as reflected in the results of the Kruskal–Wallis test.
Variations in age-normalized parameters across visits by the
same patient were lower than the variation seen between
patients, suggesting good reproducibility of AIFs. This sug-
gests that, once available, a patient’s AIF could potentially
be used in future studies on that patient.
In conclusion, an AIF is necessary to obtain absolute
estimates of CBF and CBV in DSC-MRI studies. We
showed that AIFs obtained in pediatric brain tumor patients
vary in shape and that parameters describing the shape of
the AIF show a correlation with age. The large variations
seen, good reproducibility of individual patient AIFs, and
resulting CBV values obtained suggest that measurement of
individual patient AIFs is preferable to using a population
AIF. Where individual patient AIF measurement is not pos-
sible, a pediatric population AIF could be used.
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